Shreya Prasad1, Lajhem Cambridge1, Florence Huguet2, Joanne F Chou3, Zhigang Zhang3, Abraham J Wu1, Eileen M O'Reilly4, Peter J Allen5, Karyn A Goodman6. 1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Radiation Oncology, Tenon Hospital, APHP, University Paris VI, Paris, France. 3. Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, New York. 4. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 6. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: karyn.goodman@ucdenver.edu.
Abstract
PURPOSE: We compared gastrointestinal (GI) and hematologic toxicity in patients with locally advanced pancreas cancer (LAPC) undergoing definitive chemoradiation using intensity modulated radiation therapy (IMRT) or 3-dimensional conformal radiation therapy (3D-CRT) planning. METHODS AND MATERIALS: We retrospectively studied 205 patients with LAPC undergoing IMRT (n = 134) and 3D-CRT (n = 71) between May 2003 and March 2012. Patient, tumor, and treatment characteristics and acute GI/hematology toxicity according to the Common Terminology Criteria for Adverse Events, version 3.0, were recorded. Multivariable logistic regression models were used to test association between acute grade 2+ GI and hematologic toxicity outcomes and predictors. Propensity score analysis for grade 2+ GI toxicity was performed to reduce bias for confounding variables: age, gender, radiation dose, field size, and chemotherapy type. RESULTS: Median follow-up time for survivors was 22 months and was similar between groups. Median RT dose was significantly higher for IMRT versus 3D-CRT (5600 cGy vs 5040 cGy, P < .001); concurrent chemotherapy was mainly gemcitabine (56%) or 5-fluorouracil (38%). Grade 2+ GI toxicity occurred in 34% (n = 24) of 3D-CRT compared with 16% (n = 21) of IMRT patients. Using propensity score analysis, 3D-CRT had significantly higher grade 2+ GI toxicity (odds ratio, 1.26; 95% confidence interval, 1.08-1.45; P = .001). Grade 2+ hematologic toxicity was similar between IMRT and 3D-CRT groups, but was significantly greater in recipients of concurrent gemcitabine than in 5-fluorouracil (62% vs 29%, P < .0001). CONCLUSIONS: IMRT is associated with significant lower grade 2+ GI toxicity versus 3D-CRT for patients undergoing definitive chemoradiation therapy for LAPC. Because IMRT is better tolerated at higher doses and may allow further dose escalation, potentially improving local control for this aggressive disease. Further prospective studies of dose-escalated chemoradiation using IMRT are warranted.
PURPOSE: We compared gastrointestinal (GI) and hematologic toxicity in patients with locally advanced pancreas cancer (LAPC) undergoing definitive chemoradiation using intensity modulated radiation therapy (IMRT) or 3-dimensional conformal radiation therapy (3D-CRT) planning. METHODS AND MATERIALS: We retrospectively studied 205 patients with LAPC undergoing IMRT (n = 134) and 3D-CRT (n = 71) between May 2003 and March 2012. Patient, tumor, and treatment characteristics and acute GI/hematology toxicity according to the Common Terminology Criteria for Adverse Events, version 3.0, were recorded. Multivariable logistic regression models were used to test association between acute grade 2+ GI and hematologic toxicity outcomes and predictors. Propensity score analysis for grade 2+ GI toxicity was performed to reduce bias for confounding variables: age, gender, radiation dose, field size, and chemotherapy type. RESULTS: Median follow-up time for survivors was 22 months and was similar between groups. Median RT dose was significantly higher for IMRT versus 3D-CRT (5600 cGy vs 5040 cGy, P < .001); concurrent chemotherapy was mainly gemcitabine (56%) or 5-fluorouracil (38%). Grade 2+ GI toxicity occurred in 34% (n = 24) of 3D-CRT compared with 16% (n = 21) of IMRT patients. Using propensity score analysis, 3D-CRT had significantly higher grade 2+ GI toxicity (odds ratio, 1.26; 95% confidence interval, 1.08-1.45; P = .001). Grade 2+ hematologic toxicity was similar between IMRT and 3D-CRT groups, but was significantly greater in recipients of concurrent gemcitabine than in 5-fluorouracil (62% vs 29%, P < .0001). CONCLUSIONS: IMRT is associated with significant lower grade 2+ GI toxicity versus 3D-CRT for patients undergoing definitive chemoradiation therapy for LAPC. Because IMRT is better tolerated at higher doses and may allow further dose escalation, potentially improving local control for this aggressive disease. Further prospective studies of dose-escalated chemoradiation using IMRT are warranted.
Authors: Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess Journal: JAMA Date: 2007-01-17 Impact factor: 56.272
Authors: Susannah Yovino; Matthew Poppe; Salma Jabbour; Vera David; Michael Garofalo; Naimesh Pandya; Richard Alexander; Nader Hanna; William F Regine Journal: Int J Radiat Oncol Biol Phys Date: 2010-04-14 Impact factor: 7.038
Authors: Patrick J Loehrer; Yang Feng; Higinia Cardenes; Lynne Wagner; Joanna M Brell; David Cella; Patrick Flynn; Ramesh K Ramanathan; Christopher H Crane; Steven R Alberts; Al B Benson Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Jiayi Huang; John M Robertson; Jeffrey Margolis; Savitha Balaraman; Gary Gustafson; Prem Khilanani; Laura Nadeau; Robert Jury; Bruce McIntosh Journal: Radiother Oncol Date: 2011-05-27 Impact factor: 6.280
Authors: A Yuriko Minn; Annie Hsu; Trang La; Pamela Kunz; George A Fisher; James M Ford; Jeffrey A Norton; Brendan Visser; Karyn A Goodman; Albert C Koong; Daniel T Chang Journal: Cancer Date: 2010-08-15 Impact factor: 6.860
Authors: Edgar Ben-Josef; Anthony F Shields; Ulka Vaishampayan; Vainutis Vaitkevicius; Basil F El-Rayes; Patrick McDermott; Jay Burmeister; Todd Bossenberger; Philip A Philip Journal: Int J Radiat Oncol Biol Phys Date: 2004-06-01 Impact factor: 7.038
Authors: Michael T Milano; Steven J Chmura; Michael C Garofalo; Carla Rash; John C Roeske; Phillip P Connell; Oh-Hoon Kwon; Ashesh B Jani; Ruth Heimann Journal: Int J Radiat Oncol Biol Phys Date: 2004-06-01 Impact factor: 7.038
Authors: B Chauffert; F Mornex; F Bonnetain; P Rougier; C Mariette; O Bouché; J F Bosset; T Aparicio; L Mineur; A Azzedine; P Hammel; J Butel; N Stremsdoerfer; P Maingon; L Bedenne Journal: Ann Oncol Date: 2008-05-07 Impact factor: 32.976
Authors: John M David; Sungjin Kim; Veronica R Placencio-Hickok; Arman Torosian; Andrew Hendifar; Richard Tuli Journal: Adv Radiat Oncol Date: 2018-11-09
Authors: Brandon R Mancini; Stacey Stein; Shane Lloyd; Charles E Rutter; Edward James; Bryan W Chang; Jill Lacy; Kimberly L Johung Journal: J Gastrointest Oncol Date: 2018-12
Authors: Lauren E Colbert; Shalini Moningi; Awalpreet Chadha; Ahmed Amer; Yeonju Lee; Robert A Wolff; Gauri Varadhachary; Jason Fleming; Matthew Katz; Prajnan Das; Sunil Krishnan; Eugene J Koay; Peter Park; Christopher H Crane; Cullen M Taniguchi Journal: Adv Radiat Oncol Date: 2017-03-18